Literature DB >> 21931020

Flushing oral oncology drugs down the toilet.

Mark J Ratain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21931020     DOI： 10.1200/JCO.2011.37.1617

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Reply to: Gilligan T. Is there such a thing as cancer treatment that isn't worth its cost? The oncologist 2012;17:3-4.

Authors:  Donna Marie Graham; Seamus O'Reilly
Journal:  Oncologist       Date:  2013

Review 2.  Determining the optimal dose in the development of anticancer agents.

Authors:  Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2014-03-25       Impact factor: 66.675

3.  Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.

Authors:  Vinay Prasad; Paul R Massey; Tito Fojo
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

4.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Authors:  Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

5.  Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.

Authors:  Manish R Sharma; Theodore G Karrison; Bethany Kell; Kehua Wu; Michelle Turcich; David Geary; Soonmo P Kang; Naoko Takebe; Richard A Graham; Michael L Maitland; Richard L Schilsky; Mark J Ratain; Ezra E W Cohen
Journal:  Clin Cancer Res       Date:  2013-04-03       Impact factor: 12.531

Review 6.  Abiraterone in the treatment of metastatic castration-resistant prostate cancer.

Authors:  Elahe A Mostaghel
Journal:  Cancer Manag Res       Date:  2014-01-28       Impact factor: 3.989

7.  Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.

Authors:  Jatinder Goyal; Emmanuel S Antonarakis
Journal:  Clin Med Insights Urol       Date:  2013-07-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.